Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06659471 · ClinicalTrials.gov registry record · NA
Brief Title: a Clinical Study to Assess Gingivitis
A NA study of Gingival Diseases, sponsored by Procter and Gamble.
- Completed
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06659471: Completed NA study of Gingival Diseases, sponsored by Procter and Gamble.
NCT06659471 is a NA study of Gingival Diseases that has completed, run by Procter and Gamble. The registered enrollment target is 120 participants, above the 48-participant average among 4 other Gingival Diseases trials with a reported enrollment target (150% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06659471, a NA study of Gingival Diseases, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this learning clinical study is to evaluate the effects of formulation chemistry on gingivitis.
Primary Outcome
Number of bleeding sites derived from the Löe-Silness Gingivitis Evaluation based on a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Conditions Studied
Interventions
- DRUG 0.76% Sodium Monofluorophosphate Dentifrice
- DRUG 0.454% Stannous Fluoride Dentifrice
Study Locations (1)
Nevada
- Silverstone Research - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2022-06-06 |
| Phase | NA |
What the finished NCT06659471 record still lists
NCT06659471 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 48-participant average among 4 other Gingival Diseases trials with a reported enrollment target (150% higher).
The record links to 1 condition, with Gingival Diseases appearing as the primary indexed condition, and to 2 interventions - of which 0.76% Sodium Monofluorophosphate Dentifrice is the first listed.
NCT06659471 reports a single indexed study location in Nevada.
Frequently Asked Questions
What is clinical trial NCT06659471 about?
NCT06659471 is a clinical study titled "Brief Title: a Clinical Study to Assess Gingivitis". The objective of this learning clinical study is to evaluate the effects of formulation chemistry on gingivitis.
What is the current status of trial NCT06659471?
This trial is currently completed. It is a NA study. The enrollment target is 120 participants. The study started on 2022-03-07. Estimated completion is 2022-06-06.
What conditions does trial NCT06659471 study?
This clinical trial studies the following conditions: Gingival Diseases.
What interventions are being tested in trial NCT06659471?
The interventions under investigation include: 0.76% Sodium Monofluorophosphate Dentifrice (DRUG), 0.454% Stannous Fluoride Dentifrice (DRUG).
Who is sponsoring clinical trial NCT06659471?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06659471 being conducted?
This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gingival Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Novel Dental Gel as an Adjunct to Scaling and Root Planing
RECRUITING · NA
-
OCT Vibrography for Biomechanical Properties of Tissues
RECRUITING · NA
-
Effect of Using Placental Membranes on Healing and Post-op Pain After Gum Surgery
COMPLETED · NA
-
Pilot Efficacy Study to Treat Gingivitis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI